联合放疗和唑来膦酸用于骨转移姑息治疗的安全性和有效性研究
研究联合放疗和唑来膦酸缓解乳腺癌、前列腺癌和肺癌骨转移的安全性和有效性的 I 期试验
研究概览
详细说明
骨转移通常是癌症患者播散性疾病的最初迹象之一。 转移性疾病引起的骨骼并发症包括(严重的)骨痛、活动能力受损、脊髓受压、病理性骨折和高钙血症。 放疗和手术是骨转移局部治疗的具体选择。 化疗、激素疗法和双膦酸盐是用于治疗伴或不伴高钙血症的骨转移的全身性武器。 有转移到骨骼倾向的癌症,如乳腺癌、前列腺癌、肺癌和骨髓瘤,可能具有与破骨细胞相互作用的能力。 破骨细胞是专门的骨细胞,它通过分泌酸和溶酶体酶来侵蚀矿化骨。 在正常的骨重塑中,破骨细胞的骨吸收与成骨细胞的骨形成相关并处于平衡状态。 与恶性骨转移相关的溶解性骨破坏的发生是因为肿瘤细胞合成并释放刺激破骨细胞吸收骨的可溶性因子。 破骨细胞的恶性激活导致正常骨重塑的破坏,其中骨吸收和骨形成之间的平衡向骨吸收增加的方向移动。 破骨细胞骨吸收的这种相对增加导致骨的净损失。
唑来膦酸(Zometa®,CGP42446)是一类称为双膦酸盐的化合物的成员。 双膦酸盐是破骨细胞骨吸收的有效抑制剂。 它们在治疗恶性肿瘤的高钙血症、与多发性骨髓瘤相关的溶骨病以及与乳腺癌、前列腺癌和肺癌相关的混合性溶骨性和成骨性骨转移中具有治疗功效。 在临床环境中,唑来膦酸是最有效的双膦酸盐。
传统上,外照射放疗 (RT) 是姑息骨转移的主要治疗方法。 RT 在骨转移治疗中的目的是在不损害周围正常细胞的情况下根除恶性细胞。 通常对病变区域进行放疗,以尽可能多地保留骨髓。 放疗适用于多发性骨髓瘤的孤立性、溶解性和疼痛性骨病变以及实体瘤(如乳腺癌、前列腺癌和肺癌)的骨转移,以预防骨折风险或减轻疼痛。
本研究的目的是评估联合标准放疗和标准唑来膦酸对乳腺癌、前列腺癌或肺癌患者骨转移的安全性和有效性。 我们选择唑来膦酸用于本研究,因为它是 FDA 批准的最有效的氨基双膦酸盐。
研究类型
注册 (实际的)
阶段
- 阶段1
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
纳入标准:
- >18 岁
- 活检证实为乳腺癌、肺癌和/或前列腺癌
- 有放疗指征的骨转移,经放射学诊断或活检证实
- 卡诺夫斯基表现状态 >60
- 至少6个月的预期寿命
- 血清肌酐水平 ≤ 2.0 mg/dL 和计算的肌酐清除率 > 60 mL/min
- 白细胞计数≥3500/mm3
- 血红蛋白 > 11 克/分升
- 血小板 > 100,000 / mm3
- 总胆红素 < 2.5 mg/dl
排除标准:
- 孕妇和哺乳期妇女(乳腺癌和肺癌)
- 激素疗法在随机分组前不到 3 个月开始(前列腺癌)
- 双膦酸盐过敏反应史
- 接受伴随的肾毒性化疗
- 在过去 30 天内参加过另一项研究药物的临床试验或完成了一项研究药物试验
- 肝功能检查 > 正常值的 1.5 倍
- 在随机化前 30 天内静脉注射降钙素
- 肾脏疾病的实验室证据
- 先前对骨转移区域的放疗,将在本研究中治疗
- 目前正在接受口服或静脉注射双膦酸盐治疗
- 腹水的存在
- 有临床意义的心电图改变
- 高钙血症、病理性骨折或硬膜外脊髓压迫
- 其他器官转移
- 已知对 Zometa®(唑来膦酸)或其他双膦酸盐过敏
- 当前活跃的牙齿问题,包括牙齿或颚骨(上颌骨或下颌骨)的感染;牙科或固定器外伤,或当前或之前诊断为下颌骨坏死 (ONJ)、口腔外露骨或牙科手术后愈合缓慢。
- 最近(6 周内)或计划进行牙科或颌骨手术(例如拔牙、植入)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:1个
唑来膦酸联合放疗
|
在基线 4 mg IV 唑来膦酸超过 15 分钟。
每 4 周一次,持续 6 个月,加上放疗 30 Gy,分 10 次(前两周每周 5 次)
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
正电子断层扫描
大体时间:基线和 6 个月
|
基线和 6 个月
|
次要结果测量
结果测量 |
大体时间 |
---|---|
X 射线,基线
大体时间:3个月,6个月
|
3个月,6个月
|
体检
大体时间:放射肿瘤科 - 就诊 1、14、17
|
放射肿瘤科 - 就诊 1、14、17
|
体检
大体时间:肿瘤内科 - 就诊 1、13、17
|
肿瘤内科 - 就诊 1、13、17
|
合作者和调查者
出版物和有用的链接
一般刊物
- Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, Lievshitz G, Ron I, Mishani E. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004 Feb;45(2):272-8.
- ABRAMS HL, SPIRO R, GOLDSTEIN N. Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer. 1950 Jan;3(1):74-85. doi: 10.1002/1097-0142(1950)3:13.0.co;2-7. No abstract available.
- Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain. 1998 Dec;78(3):157-169. doi: 10.1016/S0304-3959(98)00135-3.
- Scher HI, Chung LW. Bone metastases: improving the therapeutic index. Semin Oncol. 1994 Oct;21(5):630-56. No abstract available.
- Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer. 2004 Jun;11(2):207-24. doi: 10.1677/erc.0.0110207.
- Lipton A, Berenson JR. Bisphosphonate treatment of lytic bone metastases. Drugs Aging. 1999 Apr;14(4):241-6. doi: 10.2165/00002512-199914040-00001.
- Body JJ. Clinical research update: zoledronate. Cancer. 1997 Oct 15;80(8 Suppl):1699-701. doi: 10.1002/(sici)1097-0142(19971015)80:8+3.3.co;2-a.
- Mundy GR, Wilkinson R, Heath DA. Comparative study of available medical therapy for hypercalcemia of malignancy. Am J Med. 1983 Mar;74(3):421-32. doi: 10.1016/0002-9343(83)90961-0.
- Ralston SH, Gallacher SJ, Patel U, Dryburgh FJ, Fraser WD, Cowan RA, Boyle IT. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet. 1989 Nov 18;2(8673):1180-2. doi: 10.1016/s0140-6736(89)91791-1.
- Cantwell BM, Harris AL. Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer. Br Med J (Clin Res Ed). 1987 Feb 21;294(6570):467-9. doi: 10.1136/bmj.294.6570.467.
- Thiebaud D, Jaeger P, Jacquet AF, Burckhardt P. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol. 1988 May;6(5):762-8. doi: 10.1200/JCO.1988.6.5.762.
- Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer. 2000 Jun 15;88(12 Suppl):2892-8. doi: 10.1002/1097-0142(20000615)88:12+3.0.co;2-y.
- Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, Gillespie MT. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 1999 Oct;140(10):4451-8. doi: 10.1210/endo.140.10.7037.
- Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Richman SP, Tauer K, Neidhart J, Mallette LE, Siegel R, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol. 1992 Jan;10(1):134-42. doi: 10.1200/JCO.1992.10.1.134.
- Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, Henderson IC, Mallette LE. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med. 1993 Sep;95(3):297-304. doi: 10.1016/0002-9343(93)90282-t.
- Elomaa I, Blomqvist C, Grohn P, Porkka L, Kairento AL, Selander K, Lamberg-Allardt C, Holmstrom T. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet. 1983 Jan 22;1(8317):146-9. doi: 10.1016/s0140-6736(83)92755-1.
- Coleman RE, Woll PJ, Miles M, Scrivener W, Rubens RD. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Br J Cancer. 1988 Nov;58(5):621-5. doi: 10.1038/bjc.1988.272.
- Morton AR, Cantrill JA, Pillai GV, McMahon A, Anderson DC, Howell A. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ. 1988 Sep 24;297(6651):772-3. doi: 10.1136/bmj.297.6651.772. No abstract available.
- Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993 Jan;11(1):59-65. doi: 10.1200/JCO.1993.11.1.59.
- van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL, Cleton FJ, Beex LV, Blijham G, Hermans J, Neijt JP, Papapoulos SE, Sleeboom HP, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol. 1993 Mar;11(3):491-8. doi: 10.1200/JCO.1993.11.3.491.
- Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet. 1992 Oct 31;340(8827):1049-52. doi: 10.1016/0140-6736(92)93075-x. Erratum In: Lancet 1992 Dec 5;340(8832):1420.
- Man Z, Otero AB, Rendo P, Barazzutti L, Sanchez Avalos JC. Use of pamidronate for multiple myeloma osteolytic lesions. Lancet. 1990 Mar 17;335(8690):663. doi: 10.1016/0140-6736(90)90452-b. No abstract available.
- Thiebaud D, Leyvraz S, von Fliedner V, Perey L, Cornu P, Thiebaud S, Burckhardt P. Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer. 1991;27(1):37-41. doi: 10.1016/0277-5379(91)90056-j.
- Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996 Feb 22;334(8):488-93. doi: 10.1056/NEJM199602223340802.
- Shipman CM, Rogers MJ, Apperley JF, Graham R, Russell G, Croucher PI. Anti-tumour activity of bisphosphonates in human myeloma cells. Leuk Lymphoma. 1998 Dec;32(1-2):129-38. doi: 10.3109/10428199809059253.
- Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996 Dec 12;335(24):1785-91. doi: 10.1056/NEJM199612123352401.
- Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996 Sep;14(9):2552-9. doi: 10.1200/JCO.1996.14.9.2552.
- Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int. 1986 Jun;38(6):342-9. doi: 10.1007/BF02555748.
- Boonekamp PM, Lowik CW, van der Wee-Pals LJ, van Wijk-van Lennep ML, Bijvoet OL. Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Miner. 1987 Feb;2(1):29-42.
- Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int. 1991 Dec;49(6):407-15. doi: 10.1007/BF02555852.
- Reitsma PH, Teitelbaum SL, Bijvoet OL, Kahn AJ. Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro. J Clin Invest. 1982 Nov;70(5):927-33. doi: 10.1172/jci110704.
- Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, Thesing CW, Bijvoet OL. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1986 Feb;1(1):27-39.
- Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. 1989 Jun;83(6):1930-5. doi: 10.1172/JCI114100.
- Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia. 1998 Feb;12(2):220-9. doi: 10.1038/sj.leu.2400892.
- Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med. 1974 Nov 14;291(20):1041-6. doi: 10.1056/NEJM197411142912001. No abstract available.
- O'Grady RL, Cameron DA. Osteoclasts and the resorption of bone by transplanted mammary carcinoma in rats. Br J Cancer. 1985 Jun;51(6):767-74. doi: 10.1038/bjc.1985.120.
- Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE. Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med. 1980 Dec 11;303(24):1377-83. doi: 10.1056/NEJM198012113032401.
- Valentin-Opran A, Charhon SA, Meunier PJ, Edouard CM, Arlot ME. Quantitative histology of myeloma-induced bone changes. Br J Haematol. 1982 Dec;52(4):601-10. doi: 10.1111/j.1365-2141.1982.tb03936.x.
- Taube T, Elomaa I, Blomqvist C, Beneton MN, Kanis JA. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone. 1994 Mar-Apr;15(2):161-6. doi: 10.1016/8756-3282(94)90703-x.
- Mundy GR, Ibbotson KJ, D'Souza SM. Tumor products and the hypercalcemia of malignancy. J Clin Invest. 1985 Aug;76(2):391-4. doi: 10.1172/JCI111984. No abstract available.
- Garrett IR, Durie BG, Nedwin GE, Gillespie A, Bringman T, Sabatini M, Bertolini DR, Mundy GR. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med. 1987 Aug 27;317(9):526-32. doi: 10.1056/NEJM198708273170902.
- Cozzolino F, Torcia M, Aldinucci D, Rubartelli A, Miliani A, Shaw AR, Lansdorp PM, Di Guglielmo R. Production of interleukin-1 by bone marrow myeloma cells. Blood. 1989 Jul;74(1):380-7.
- Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999 Jul;25(1):97-106. doi: 10.1016/s8756-3282(99)00116-7.
- Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J, Auriola S, Chilton KM, Russell RG. Molecular mechanisms of action of bisphosphonates. Bone. 1999 May;24(5 Suppl):73S-79S. doi: 10.1016/s8756-3282(99)00070-8. No abstract available.
- Jung A, Bornand J, Mermillod B, Edouard C, Meunier PJ. Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat. Cancer Res. 1984 Jul;44(7):3007-11.
- Radl J, Croese JW, Zurcher C, van den Enden-Vieveen MH, Brondijk RJ, Kazil M, Haaijman JJ, Reitsma PH, Bijvoet OL. Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer. 1985 Mar 1;55(5):1030-40. doi: 10.1002/1097-0142(19850301)55:53.0.co;2-y.
- Nemoto R, Sato S, Nishijima Y, Miyakawa I, Koiso K, Harada M. Effects of a new bisphosphonate (AHBuBP) on osteolysis induced by human prostate cancer cells in nude mice. J Urol. 1990 Sep;144(3):770-4. doi: 10.1016/s0022-5347(17)39589-7.
- Nemoto R, Satou S, Miyagawa I, Koiso K. Inhibition by a new bisphosphonate (AHBuBP) of bone resorption induced by the MBT-2 tumor of mice. Cancer. 1991 Feb 1;67(3):643-8. doi: 10.1002/1097-0142(19910201)67:33.0.co;2-w.
- Sawyer N, Newstead C, Drummond A, Cunningham J. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia. Bone Miner. 1990 May;9(2):121-8. doi: 10.1016/0169-6009(90)90078-t.
- Body JJ, Magritte A, Seraj F, Sculier JP, Borkowski A. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions. J Bone Miner Res. 1989 Dec;4(6):923-8. doi: 10.1002/jbmr.5650040617.
- Body JJ, Borkowski A, Cleeren A, Bijvoet OL. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J Clin Oncol. 1986 Aug;4(8):1177-83. doi: 10.1200/JCO.1986.4.8.1177.
- Coleman RE, Rubens RD. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer. Br J Cancer. 1987 Oct;56(4):465-9. doi: 10.1038/bjc.1987.225.
- Mundy GR, Ibbotson KJ, D'Souza SM, Simpson EL, Jacobs JW, Martin TJ. The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med. 1984 Jun 28;310(26):1718-27. doi: 10.1056/NEJM198406283102607. No abstract available.
- Martin TJ. Humoral hypercalcemia of malignancy. Bone Miner. 1988 Apr;4(1):83-9. No abstract available.
- Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int. 1983;35(1):87-99. doi: 10.1007/BF02405012.
- Kellihan MJ, Mangino PD. Pamidronate. Ann Pharmacother. 1992 Oct;26(10):1262-9. doi: 10.1177/106002809202601015.
- Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994 May;9(5):745-51. doi: 10.1002/jbmr.5650090521.
- Berenson JR, Vescio R, Henick K, Nishikubo C, Rettig M, Swift RA, Conde F, Von Teichert JM. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer. 2001 Jan 1;91(1):144-54. doi: 10.1002/1097-0142(20010101)91:13.0.co;2-q.
- Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res. 1999 Sep;14(9):1557-61. doi: 10.1359/jbmr.1999.14.9.1557.
- Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest. 2002;20 Suppl 2:45-54. doi: 10.1081/cnv-120014886.
- Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer. 2000 Feb;82(4):858-64. doi: 10.1054/bjoc.1999.1012.
- Binkley N, Kimmel D, Bruner J, Haffa A, Davidowitz B, Meng C, Schaffer V, Green J. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res. 1998 Nov;13(11):1775-82. doi: 10.1359/jbmr.1998.13.11.1775.
- Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000 Apr;82(8):1459-68. doi: 10.1054/bjoc.1999.1131.
- Teronen O, Heikkila P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P, Sorsa T. MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci. 1999 Jun 30;878:453-65. doi: 10.1111/j.1749-6632.1999.tb07702.x.
- Tassone P, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli V, Tagliaferri P, Venuta S. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia. 2000 May;14(5):841-4. doi: 10.1038/sj.leu.2401770.
- Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000 Jun 1;60(11):2949-54.
- Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001 Apr 20;84(8):1126-34. doi: 10.1054/bjoc.2001.1727.
- Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001 Mar 15;61(6):2602-8.
- Riebeling C, Forsea AM, Raisova M, Orfanos CE, Geilen CC. The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br J Cancer. 2002 Jul 29;87(3):366-71. doi: 10.1038/sj.bjc.6600476.
- Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs. 2001 Jun;12(5):459-65. doi: 10.1097/00001813-200106000-00007.
- Mackie PS, Fisher JL, Zhou H, Choong PF. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer. 2001 Apr 6;84(7):951-8. doi: 10.1054/bjoc.2000.1679.
- Magnetto S, Boissier S, Delmas PD, Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer. 1999 Oct 8;83(2):263-9. doi: 10.1002/(sici)1097-0215(19991008)83:23.0.co;2-t.
- Percival RC, Urwin GH, Harris S, Yates AJ, Williams JL, Beneton M, Kanis JA. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol. 1987 Feb;13(1):41-9.
- Ikeda I, Miura T, Kondo I. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br J Urol. 1996 Jan;77(1):102-6. doi: 10.1046/j.1464-410x.1996.82817.x.
- Takeuchi S, Arai K, Saitoh H, Yoshida K, Miura M. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol. 1996 Nov;156(5):1691-5.
- Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol. 1991 Jul;68(1):74-80. doi: 10.1111/j.1464-410x.1991.tb15260.x.
- Coleman RE, Houston S, James I, Rodger A, Rubens RD, Leonard RC, Ford J. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. Br J Cancer. 1992 May;65(5):766-8. doi: 10.1038/bjc.1992.161.
- Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer. 1996 May;73(9):1089-95. doi: 10.1038/bjc.1996.210.
- Clarke NW, McClure J, George NJ. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol. 1992 Jan;69(1):64-70. doi: 10.1111/j.1464-410x.1992.tb15461.x.
- Adami S, Salvagno G, Guarrera G, Bianchi G, Dorizzi R, Rosini S, Mobilio G, Lo Cascio V. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol. 1985 Dec;134(6):1152-4. doi: 10.1016/s0022-5347(17)47663-4.
- Masud T, Slevin ML. Pamidronate to reduce bone pain in normocalcaemic patient with disseminated prostatic carcinoma. Lancet. 1989 May 6;1(8645):1021-2. doi: 10.1016/s0140-6736(89)92665-2. No abstract available.
- Pelger RC, Lycklama a Nijeholt AA, Papapoulos SE. Short-term metabolic effects of pamidronate in patients with prostatic carcinoma and bone metastases. Lancet. 1989 Oct 7;2(8667):865. doi: 10.1016/s0140-6736(89)93028-6. No abstract available.
- Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001 Sep-Oct;7(5):377-87.
- Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003 Oct 15;98(8):1735-44. doi: 10.1002/cncr.11701.
- Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B; Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68. doi: 10.1093/jnci/94.19.1458.
- Saad F, Chi K, Fleshner N. The role of bisphosphonates in the management of bone metastases in prostate cancer. Can J Urol. 2004 Oct;11(5):2376-82.
- Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003 Aug 15;21(16):3150-7. doi: 10.1200/JCO.2003.04.105.
- Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004 Jun 15;100(12):2613-21. doi: 10.1002/cncr.20308.
- Major RJ, Chen BL, et al. Multiple event analysis of zoledronic acid trials in patients with cancer metastatic to bone. Proc Am Soc Clin Oncol 22:762, 2003
- Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004 Jan 1;100(1):36-43. doi: 10.1002/cncr.11892.
- Coleman RE. Bisphosphonates: clinical experience. Oncologist. 2004;9 Suppl 4:14-27. doi: 10.1634/theoncologist.9-90004-14.
- Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F. Renal failure associated with intravenous diphosphonates. Lancet. 1983 Feb 26;1(8322):471. doi: 10.1016/s0140-6736(83)91465-4. No abstract available.
- Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG. Effects of intravenous diphosphonates on renal function. Lancet. 1983 Jun 11;1(8337):1328. doi: 10.1016/s0140-6736(83)92434-0. No abstract available.
- Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res Ed). 1987 Nov 21;295(6609):1301-5. doi: 10.1136/bmj.295.6609.1301.
- Green JR, Seltenmeyer Y, Jaeggi KA, Widler L. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol. 1997 May;80(5):225-30. doi: 10.1111/j.1600-0773.1997.tb01964.x.
- Falkmer U, Jarhult J, Wersall P, Cavallin-Stahl E. A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol. 2003;42(5-6):620-33. doi: 10.1080/02841860310014895.
- Kagan AR, Rose CM, Bedwinek JM, Blitzer PH, Brascho DJ, Brown AP, Coia LR, Earle JD, Janjan NA, Lowy RO, Pieters RS Jr, Rotman M, Leibel SA. Bone metastases. American College of Radiology. ACR Appropriateness Criteria. Radiology. 2000 Jun;215 Suppl:1077-104. No abstract available.
- Rose CM, Kagan AR. The final report of the expert panel for the radiation oncology bone metastasis work group of the American College of Radiology. Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1117-24. doi: 10.1016/s0360-3016(97)00952-8.
- Chow E, Danjoux C, Wong R, Szumacher E, Franssen E, Fung K, Finkelstein J, Andersson L, Connolly R. Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists. Radiother Oncol. 2000 Sep;56(3):305-14. doi: 10.1016/s0167-8140(00)00238-3.
- Vakaet LA, Boterberg T. Pain control by ionizing radiation of bone metastasis. Int J Dev Biol. 2004;48(5-6):599-606. doi: 10.1387/ijdb.041817lv.
- Koswig S, Budach V. [Remineralization and pain relief in bone metastases after after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study]. Strahlenther Onkol. 1999 Oct;175(10):500-8. doi: 10.1007/s000660050061. German.
- Hoskin PJ, Stratford MR, Folkes LK, Regan J, Yarnold JR. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet. 2000 Apr 22;355(9213):1428-9. doi: 10.1016/s0140-6736(00)02144-9.
- Algur E, Macklis RM, Hafeli UO. Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):535-42. doi: 10.1016/j.ijrobp.2004.09.065.
- Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer. 1982 Sep 1;50(5):893-9. doi: 10.1002/1097-0142(19820901)50:53.0.co;2-y.
- Blitzer PH. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer. 1985 Apr 1;55(7):1468-72. doi: 10.1002/1097-0142(19850401)55:73.0.co;2-m.
- Price P, Hoskin PJ, Easton D, Austin D, Palmer SG, Yarnold JR. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol. 1986 Aug;6(4):247-55. doi: 10.1016/s0167-8140(86)80191-8.
- Hoskin PJ, Price P, Easton D, Regan J, Austin D, Palmer S, Yarnold JR. A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol. 1992 Feb;23(2):74-8. doi: 10.1016/0167-8140(92)90338-u.
- Rasmusson B, Vejborg I, Jensen AB, Andersson M, Banning AM, Hoffmann T, Pfeiffer P, Nielsen HK, Sjogren P. Irradiation of bone metastases in breast cancer patients: a randomized study with 1 year follow-up. Radiother Oncol. 1995 Mar;34(3):179-84. doi: 10.1016/0167-8140(95)01520-q.
- Steenland E, Leer JW, van Houwelingen H, Post WJ, van den Hout WB, Kievit J, de Haes H, Martijn H, Oei B, Vonk E, van der Steen-Banasik E, Wiggenraad RG, Hoogenhout J, Warlam-Rodenhuis C, van Tienhoven G, Wanders R, Pomp J, van Reijn M, van Mierlo I, Rutten E. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol. 1999 Aug;52(2):101-9. doi: 10.1016/s0167-8140(99)00110-3. Erratum In: Radiother Oncol 1999 Nov;53(2):167. Leer, J [corrected to Leer, JW]; van Mierlo ,T [corrected to van Mierlo, I].
- Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003 Jun 19;348(25):2500-7. doi: 10.1056/NEJMoa022136.
- Bienert M, McCook B, Carr BI, Geller DA, Sheetz M, Tutor C, Amesur N, Avril N. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):778-87. doi: 10.1007/s00259-004-1752-1. Epub 2005 Mar 17.
- Ishimori T, Saga T, Nagata Y, Nakamoto Y, Higashi T, Mamede M, Mukai T, Negoro Y, Aoki T, Hiraoka M, Konishi J. 18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann Nucl Med. 2004 Dec;18(8):669-74. doi: 10.1007/BF02985960.
- Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med. 1995 Oct;36(10):1836-9. No abstract available.
- Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 1993 Dec;189(3):847-50. doi: 10.1148/radiology.189.3.8234714.
- Hiraga T, Ueda A, Tamura D, Hata K, Ikeda F, Williams PJ, Yoneda T. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int J Cancer. 2003 Oct 10;106(6):973-9. doi: 10.1002/ijc.11330.
- Witters LM, Crispino J, Fraterrigo T, Green J, Lipton A. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol. 2003 Aug;26(4):S92-7. doi: 10.1097/01.COC.0000074165.90133.40.
- Kouloulias V, Matsopoulos G, Kouvaris J, Dardoufas C, Bottomley A, Varela M, Uzunoglu N, Antypas C, Metafa A, Moulopoulos A, Sandilos P, Vlahos L. Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using assessments of gray-level histogram in plain radiographs. Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):143-57. doi: 10.1016/s0360-3016(03)00525-x.
- Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kuhn T, Kreienberg R, Messer P, Nussle K, Elsner K, Glatting G, Trager H, Neumaier B, Diederichs C, Reske SN. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999 Aug;17(8):2381-9. doi: 10.1200/JCO.1999.17.8.2381.
- Peterson JJ, Kransdorf MJ, O'Connor MI. Diagnosis of occult bone metastases: positron emission tomography. Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S120-8. doi: 10.1097/01.blo.0000093051.96273.7c.
- Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, Meyer GJ, Karstens JH, Knapp WH, Boerner AR. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2003 Apr;30(4):607-11. doi: 10.1007/s00259-002-1104-y. Epub 2003 Feb 13.
研究记录日期
研究主要日期
学习开始
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
唑来膦酸的临床试验
-
Gladwin, Mark, MDNational Heart, Lung, and Blood Institute (NHLBI); Complexa, Inc.终止
-
University of Colorado, DenverNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH)招聘中
-
University College, LondonImperial College London; Cancer Research UK; National Cancer Imaging Translational Accelerator招聘中